<DOC>
	<DOCNO>NCT02362152</DOCNO>
	<brief_summary>This non-interventional , multinational study topical field treatment actinic keratosis ( AK ) aim collect real-life experience ingenol mebutate well one two topical field therapy commonly use individual country . Physicians report baseline characteristic , main study focus patient report outcomes 3-4 week treatment completion ( treatment satisfaction , adherence , resource utilization Health Related Quality Life . Dermatology centre Denmark , Norway , Sweden , Netherlands , United Kingdom Canada participate .</brief_summary>
	<brief_title>The Real Life Topical Field Treatment Actinic Keratosis Study</brief_title>
	<detailed_description>Actinic keratosis ( AK ) cause exposure UV radiation potential regress normal skin squamous cell carcinoma . AK treatment option include cryotherapy solitary lesion topical field therapy photodynamic therapy lesion area sun-damaged skin . This prospective , non-interventional , multinational study aim describe compare real-life set treatment satisfaction , treatment adherence , resource utilization quality life topical field treatment AK 5-fluorouracil , imiquimod , diclofenac ingenol mebutate . Dermatology centre Denmark , Sweden , Norway , Canada , United Kingdom Netherlands aim include total approximately 1600 patient , around 100 country patient schedule receive treatment ingenol mebutate . In country patient addition recruit one two treatment arm , appropriate country . Only adult patient schedule start treatment imiquimod , 5-fluorouracil , diclofenac ingenol mebutate give informed consent use data medical record study report study data include followed duration schedule treatment + 3-4 week . Physician report patient demographic AK characteristic baseline . Patients baseline report AK Quality Life , include general attitude regard sun damage skin baseline , , applicable , treatment satisfaction adherence late previous AK treatment . At 3-4 week end treatment , patient report treatment satisfaction , adherence , resource utilization , health relate Quality Life . Treating physician report drug-related Adverse Events accordance national law regulation normal clinical practice .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Patients eligible receive topical treatment one follow treatment actinic keratosis discretion dermatologist : Ingenol mebutate , 5fluorouracil , imiquimod , diclofenac . Informed consent . Any ongoing treatment study start ingenol mebutate , 5fluorouracil , imiquimod diclofenac ; topical treatment AK treatment area ; pregnancy plan pregnancy within treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Actinic keratosis</keyword>
	<keyword>Solar keratosis</keyword>
	<keyword>Field treatment</keyword>
	<keyword>Ingenol mebutate</keyword>
	<keyword>Picato</keyword>
</DOC>